Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells

Jonathan P. Sleeman, Sigrid Arming, Jürgen F. Moll, Armin Hekele, Wolfgang Rudy, Lawrence (Larry) Sherman, Günther Kreil, Helmut Ponta, Peter Herrlich

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Several studies have demonstrated a correlation between the expression of CD44 variant isoforms and the ability of tumor cells to metastasize. The CD44 proteins carry amino acid sequence motifs that confer the ability to hind to the extracellular matrix component hyaluronate (HA). In this study, we investigated whether a CD44 variant previously shown to stimulate metastasis in a rat pancreatic carcinoma model (BSp73AS) is capable of binding to HA, and whether such binding is critical for metastasis. We show that transfection of this CD44 variant into BSp73AS cells increases the HA- binding capacity of the cells in a dose-dependent manner. Transfection of the same CD44 variant isoform into BDX2 cells also conferred strong HA-binding properties on these cells, but was insufficient to cause them to metastasize. Transfection of a surface-hound hyaluronidase into metastasizing BSp73AS cells bearing variant CD44 efficiently ablated the ability of these cells to bind to HA. However, in metastasis assays, these hyaluronidase-transfected cells showed patterns of metastasis similar to those of the parental cell line. We also show that the HA-binding capacity of a variety of tumor cells is not correlated with their metastatic proclivity, and that an antibody previously shown to block metastasis of the pancreatic carcinoma cells does not interfere with their ability to bind to HA. We conclude that although CD44 variant expression does promote metastasis formation, HA binding by tumor cells is not rate limiting for metastasis in the BSp73AS system and probably also in other metastasizing tumors. Furthermore, for metastasis by CD44 variant-expressing BSp73AS cells to occur, contact of the CD44 variant protein with a ligand other than HA is required.

Original languageEnglish (US)
Pages (from-to)3134-3141
Number of pages8
JournalCancer Research
Volume56
Issue number13
StatePublished - Jul 1 1996
Externally publishedYes

Fingerprint

Neoplasm Metastasis
Aptitude
Transfection
Hyaluronoglucosaminidase
Pancreatic Carcinoma
Neoplasms
Protein Isoforms
Amino Acid Motifs
Extracellular Matrix
Amino Acid Sequence
Proteins
Ligands
Cell Line
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sleeman, J. P., Arming, S., Moll, J. F., Hekele, A., Rudy, W., Sherman, L. L., ... Herrlich, P. (1996). Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Cancer Research, 56(13), 3134-3141.

Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. / Sleeman, Jonathan P.; Arming, Sigrid; Moll, Jürgen F.; Hekele, Armin; Rudy, Wolfgang; Sherman, Lawrence (Larry); Kreil, Günther; Ponta, Helmut; Herrlich, Peter.

In: Cancer Research, Vol. 56, No. 13, 01.07.1996, p. 3134-3141.

Research output: Contribution to journalArticle

Sleeman, JP, Arming, S, Moll, JF, Hekele, A, Rudy, W, Sherman, LL, Kreil, G, Ponta, H & Herrlich, P 1996, 'Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells', Cancer Research, vol. 56, no. 13, pp. 3134-3141.
Sleeman JP, Arming S, Moll JF, Hekele A, Rudy W, Sherman LL et al. Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Cancer Research. 1996 Jul 1;56(13):3134-3141.
Sleeman, Jonathan P. ; Arming, Sigrid ; Moll, Jürgen F. ; Hekele, Armin ; Rudy, Wolfgang ; Sherman, Lawrence (Larry) ; Kreil, Günther ; Ponta, Helmut ; Herrlich, Peter. / Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. In: Cancer Research. 1996 ; Vol. 56, No. 13. pp. 3134-3141.
@article{ef56216902c242a2b753ee7c32842141,
title = "Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells",
abstract = "Several studies have demonstrated a correlation between the expression of CD44 variant isoforms and the ability of tumor cells to metastasize. The CD44 proteins carry amino acid sequence motifs that confer the ability to hind to the extracellular matrix component hyaluronate (HA). In this study, we investigated whether a CD44 variant previously shown to stimulate metastasis in a rat pancreatic carcinoma model (BSp73AS) is capable of binding to HA, and whether such binding is critical for metastasis. We show that transfection of this CD44 variant into BSp73AS cells increases the HA- binding capacity of the cells in a dose-dependent manner. Transfection of the same CD44 variant isoform into BDX2 cells also conferred strong HA-binding properties on these cells, but was insufficient to cause them to metastasize. Transfection of a surface-hound hyaluronidase into metastasizing BSp73AS cells bearing variant CD44 efficiently ablated the ability of these cells to bind to HA. However, in metastasis assays, these hyaluronidase-transfected cells showed patterns of metastasis similar to those of the parental cell line. We also show that the HA-binding capacity of a variety of tumor cells is not correlated with their metastatic proclivity, and that an antibody previously shown to block metastasis of the pancreatic carcinoma cells does not interfere with their ability to bind to HA. We conclude that although CD44 variant expression does promote metastasis formation, HA binding by tumor cells is not rate limiting for metastasis in the BSp73AS system and probably also in other metastasizing tumors. Furthermore, for metastasis by CD44 variant-expressing BSp73AS cells to occur, contact of the CD44 variant protein with a ligand other than HA is required.",
author = "Sleeman, {Jonathan P.} and Sigrid Arming and Moll, {J{\"u}rgen F.} and Armin Hekele and Wolfgang Rudy and Sherman, {Lawrence (Larry)} and G{\"u}nther Kreil and Helmut Ponta and Peter Herrlich",
year = "1996",
month = "7",
day = "1",
language = "English (US)",
volume = "56",
pages = "3134--3141",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells

AU - Sleeman, Jonathan P.

AU - Arming, Sigrid

AU - Moll, Jürgen F.

AU - Hekele, Armin

AU - Rudy, Wolfgang

AU - Sherman, Lawrence (Larry)

AU - Kreil, Günther

AU - Ponta, Helmut

AU - Herrlich, Peter

PY - 1996/7/1

Y1 - 1996/7/1

N2 - Several studies have demonstrated a correlation between the expression of CD44 variant isoforms and the ability of tumor cells to metastasize. The CD44 proteins carry amino acid sequence motifs that confer the ability to hind to the extracellular matrix component hyaluronate (HA). In this study, we investigated whether a CD44 variant previously shown to stimulate metastasis in a rat pancreatic carcinoma model (BSp73AS) is capable of binding to HA, and whether such binding is critical for metastasis. We show that transfection of this CD44 variant into BSp73AS cells increases the HA- binding capacity of the cells in a dose-dependent manner. Transfection of the same CD44 variant isoform into BDX2 cells also conferred strong HA-binding properties on these cells, but was insufficient to cause them to metastasize. Transfection of a surface-hound hyaluronidase into metastasizing BSp73AS cells bearing variant CD44 efficiently ablated the ability of these cells to bind to HA. However, in metastasis assays, these hyaluronidase-transfected cells showed patterns of metastasis similar to those of the parental cell line. We also show that the HA-binding capacity of a variety of tumor cells is not correlated with their metastatic proclivity, and that an antibody previously shown to block metastasis of the pancreatic carcinoma cells does not interfere with their ability to bind to HA. We conclude that although CD44 variant expression does promote metastasis formation, HA binding by tumor cells is not rate limiting for metastasis in the BSp73AS system and probably also in other metastasizing tumors. Furthermore, for metastasis by CD44 variant-expressing BSp73AS cells to occur, contact of the CD44 variant protein with a ligand other than HA is required.

AB - Several studies have demonstrated a correlation between the expression of CD44 variant isoforms and the ability of tumor cells to metastasize. The CD44 proteins carry amino acid sequence motifs that confer the ability to hind to the extracellular matrix component hyaluronate (HA). In this study, we investigated whether a CD44 variant previously shown to stimulate metastasis in a rat pancreatic carcinoma model (BSp73AS) is capable of binding to HA, and whether such binding is critical for metastasis. We show that transfection of this CD44 variant into BSp73AS cells increases the HA- binding capacity of the cells in a dose-dependent manner. Transfection of the same CD44 variant isoform into BDX2 cells also conferred strong HA-binding properties on these cells, but was insufficient to cause them to metastasize. Transfection of a surface-hound hyaluronidase into metastasizing BSp73AS cells bearing variant CD44 efficiently ablated the ability of these cells to bind to HA. However, in metastasis assays, these hyaluronidase-transfected cells showed patterns of metastasis similar to those of the parental cell line. We also show that the HA-binding capacity of a variety of tumor cells is not correlated with their metastatic proclivity, and that an antibody previously shown to block metastasis of the pancreatic carcinoma cells does not interfere with their ability to bind to HA. We conclude that although CD44 variant expression does promote metastasis formation, HA binding by tumor cells is not rate limiting for metastasis in the BSp73AS system and probably also in other metastasizing tumors. Furthermore, for metastasis by CD44 variant-expressing BSp73AS cells to occur, contact of the CD44 variant protein with a ligand other than HA is required.

UR - http://www.scopus.com/inward/record.url?scp=0029891775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029891775&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 3134

EP - 3141

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -